23 results about "Booster immunizations" patented technology

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and / or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime / boost vaccination strategy.

The application belongs to the field of marine biotechnology, and specifically discloses a preparation method of a long oyster insulin-like peptide receptor (ILPR) polyclonal antibody and application thereof. The method is characterized by the following steps: specific antigen epitopes of the long oyster ILPR protein are screened through bioinformatics analysis, a pET32a-ILPR recombinant plasmid is constructed and induced to express in Escherichia coli; the purified recombinant protein is used as an immunogen to immunize New Zealand white rabbits, and rabbit antisera are collected after four times of booster immunization; specific polyclonal antibodies are purified by using antigen affinity chromatography technology, and can specifically recognize the ILPR protein in long oyster tissues. The antibody prepared by the application has high specificity and sensitivity, and provides an important biological tool for studying the insulin signal transduction pathway, growth regulation and energy metabolism mechanism of long oysters.

The present invention relates i.a. to a method for treating or preventing avian influenza virus infections in avians comprising a first administration of an effective amount of a rHVT-H5HA COBRA and a second administration of an effective amount of an inactivated H5 vaccine or H5HA protein.

The invention relates to the technical field of biological medicines, and particularly discloses an egg yolk antibody for resisting canine interleukin as well as a preparation method and application of the egg yolk antibody. The egg yolk antibody is prepared by taking immunocompetence antigen epitope peptide of canine interleukin-31 as an immunogen, the antigen epitope peptide is obtained by predicting key antigen epitopes of IL-31 through an Antigenic tool and performing series optimization, a coding gene of the antigen epitope peptide is optimized by an escherichia coli codon to construct a recombinant expression vector, and high-purity antigen is obtained by inducible expression and purification. A laying hen is immunized by the antigen, after basic immunization and two times of booster immunization, the egg yolk antibody is extracted from egg yolk and purified to obtain the egg yolk antibody, and the ELISA of the egg yolk antibody is obviously superior to that of an antibody prepared by commercial canine IL-31 protein immunization. The egg yolk antibody can be specifically combined with canine IL-31, the histamine level in serum of a canine with pruritus is remarkably reduced, the atopic dermatitis related pruritus symptoms are effectively relieved, an efficient and safe biological treatment preparation is provided for canine IL-31 mediated pruritus diseases, and the egg yolk antibody has wide clinical application prospects.

The invention relates to the technical field of medicine, in particular to an antigen double burst release self-boosting immune vaccine and application thereof.The antigen double burst release self-boosting immune vaccine is characterized in that antigens are loaded inside and outside complex coacervation microcapsules in the vaccine, nanoparticles are prepared through a nanoprecipitation method, the nanoparticles and cell membranes jointly entrap the antigens to form functional nanoparticles, and the functional nanoparticles are used as functional nanoparticles; the preparation method comprises the following steps: coating functionalized nanoparticles by using a micro-fluidic technology and a complex coagulation method to prepare microcapsules, coating the surface of the microcapsules by using dopamine hydrochloride auto-polymerization reaction to form coating microcapsules, and finally blending with the functionalized nanoparticles, thereby dividing the antigen into an inner part and an outer part. After entering a body, the nano-microparticle carrier double burst release vaccine is subjected to antigen double burst release with time lag intervals in different time periods; the prepared vaccine can release antigens firstly, then effectively collect and activate antigen presenting cells, the antigen presenting cells uptake the antigen presenting cells to cause immune response, and the generation of specific antibodies can be effectively induced by two times of antigen release through the time-delay coating, so that a traditional natural immune procedure is simulated.

Abstract The present disclosure provides a method for vaccinating a subject against a mucosal virus 5 infection, comprising administering to the subject an immunologically effective amount of an intranasal booster, wherein the intranasal booster comprises detoxified Escherichia coli labile toxin (LT) and an antigen from the mucosal virus, and wherein the subject has been previously primed. An intranasal vaccine composition comprising an immunologically effective amount of a mucosal virus antigen adjuvanted with a detoxified Escherichia coli labile toxin (LT) is also .0 provided. ~22~ Sep 2023 Abstract 5 2023237105 27 ~22~

The invention discloses a method for preparing a high-titer polyclonal antibody from a Zika virus strain, which comprises the following steps: selecting the Zika virus strain, culturing in cells, and purifying virus particles with high purity to prepare an immunogen; an optimized animal immunization strategy is adopted and comprises the steps of selecting a proper host animal, applying a potent immunologic adjuvant, namely a Freund's adjuvant, and designing a scientific immunization program, so that humoral immune response of the host is stimulated to the maximum extent; when the titer of the antibody reaches a peak value, collecting antiserum, synthesizing hybridoma cells through splenocytes, and obtaining the high-purity polyclonal antibody through a multi-step purification technology. According to the method, high-purity and non-chemically-inactivated whole virus particles which retain natural conformation are used as immunogens, a mode of primary immunization and multiple booster immunization is adopted, a Freund's adjuvant is combined, animals are continuously stimulated to generate high-titer antibodies, non-specific antibodies and impurities are effectively removed through multi-step purification, and the immunogen immunogen is obtained. The target antibody with high purity and high specificity is obtained.

This invention provides a monoclonal antibody against the VP2 protein of a mandarin fish two-segmented RNA virus, its preparation method, and its application. The VP2 protein was obtained by expression and purification using recombinant plasmids. Mice were immunized three times, and mice with the highest serum titer were selected for intraperitoneal booster immunization against VP2 protein. Mouse spleen cells and SP2 / 0 myeloma cells were fused, and hybridoma cell lines secreting VP2 protein antibodies were screened. These cells were then subcloned to obtain four stable hybridoma cell lines secreting anti-VP2 protein antibodies, and their heavy and light chain variable region sequences were determined. Mice were injected intraperitoneally with Freund's incomplete adjuvant, followed by the injection of the hybridoma cell lines. Ascites fluid was collected from the mice, extracted, purified, and used to obtain the monoclonal antibody against the VP2 protein. Using these four monoclonal antibodies, three highly conserved and specific antigenic epitopes of the VP2 protein of the mandarin fish two-segmented RNA virus were screened and identified. This invention provides support for establishing specific serological methods for mandarin fish two-segmented RNA viruses and for further research on the biological function and clinical diagnosis of VP2.

The present application relates to a kind of anti-recombination canine interleukin-1β yolk antibody and its preparation method and application, the preparation method utilizes genetic engineering prokaryotic expression preparation antigen recombination canine interleukin-1β, antigen recombination canine interleukin-1β is emulsified after first immunization egg chicken with first immunoadjuvant, again the recombination canine interleukin-1β antigen is emulsified to egg chicken with second immunoadjuvant, and egg chicken is strengthened immunization, collect egg, separate egg yolk and extract the antibody in the yolk of egg, successfully obtain anti-recombination canine interleukin-1β yolk antibody, the titer of the yolk antibody is 1:409600, and higher purity, with better specificity and stability, can provide stable antigen and antibody material basis for canine IL-1β related detection, antibody preparation and subsequent application research, with wide application prospect.

An aspect provides a vaccine composition for preventing tuberculosis comprising chorismate mutase. The vaccine composition alone may induce immunity specific to Mycobacterium tuberculosis, and when provided together with an immune adjuvant, the vaccine composition may induce immunity specific to tuberculosis more effectively. Furthermore, when an existing vaccine for tuberculosis is used as a prime and the vaccine composition according to an aspect including chorismite mutase is provided as a booster, the immunity specific to tuberculosis may be induced significantly more effectively.

The present invention relates to an intestinal microorganism-based composition for enhancing the efficacy of vaccinations, in particular, the persistence of antibody reactions and booster effects. The present inventors have found that specific intestinal microorganisms are significantly abundant in individuals having a long antibody half-life following vaccination with an mRNA vaccine or an adenovirus vector vaccine, or exhibiting a high immune response upon booster vaccination. Specifically, it was found that a specific microbial community including Faecalibacterium prausnitzii is associated with antibody persistence and booster response enhancement following mRNA vaccination, and Escherichia coli is associated with antibody persistence following adenovirus vector vaccination.

The invention relates to combinations for treating or preventing cancer comprising a closed linear DNA molecule and an mRNA molecule. The invention also relates to a closed linear DNA molecule and an mRNA molecule for use in a heterologous prime-boost immunization regimen in a subject. In addition, the invention relates to methods and kits incorporating and / or using the closed linear DNA molecule and the mRNA molecule.

The invention relates to the technical field of veterinary biological products, in particular to a preparation method of a mixed vaccine for combined immunization of foot-and-mouth disease and other pig live vaccines and an immunization method. The preparation method of the mixed vaccine for combined immunization of the foot-and-mouth disease and other pig live vaccines comprises the following steps: heating the foot-and-mouth disease inactivated vaccine to 20-25 DEG C, using the foot-and-mouth disease inactivated vaccine as a dilution matrix, dissolving the pig live vaccines needing combined immunization, and uniformly mixing to form a stable emulsion, thereby obtaining the mixed vaccine. According to the mixed vaccine disclosed by the invention, the immunological injection times are reduced, and the stress and cross infection risks of pigs are reduced; it is ensured that the titer of antibodies corresponding to all vaccines after combined immunization reaches the protection standard, and the immunization effect is better than that of independent immunization or simple mixed immunization; the method is simple to operate, low in cost and suitable for popularization and application in the aspect of enhancing immunity in large-scale pig farms.

The invention discloses a construction method and application of an anti-NMDAR encephalitis disease animal model. The construction method comprises the following steps: mixing a GluN1 (359-378) peptide fragment and mycobacterium tuberculosis (Mtb) into an incomplete Freund adjuvant to obtain an emulsified mixture, performing subcutaneous injection to two sides of the back of an anesthetized mouse, and performing intraperitoneal injection of a pertussis toxin (PTX) solution; injecting the PTX solution with the same concentration into the abdominal cavity of the mouse after 48 hours; after 14 days, repeating the first operation to carry out secondary boosted immunization on the mouse; injecting the PTX solution into the abdominal cavity again after 16 days; and after 32-35 days, biological detection is carried out to determine that modeling succeeds. According to the construction method, the period is greatly shortened, and the experiment efficiency is improved; according to the method, through an optimized immune scheme, the model success rate is high, and the phenotype is stable; the model is an active immune model and can simulate a complete disease process from autoantibody generation and immune cell infiltration to central nervous system injury.

The present invention provides compositions, vaccines and methods for inducing protective immunity against an immunogen in humans. The protective immune response is obtained by using a saRNA, in particular a VRP vector as prime and a MVA for boost. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus such as EBV.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody for HPV16 type E7 protein detection and application of the monoclonal antibody. E7 protein serving as an antigen and a Freund's complete adjuvant are mixed, then a mouse is subjected to primary immunization, then the E7 protein and a Freund's incomplete adjuvant are mixed, then the mouse is subjected to enhanced immunization, and the HPV16 type E7 protein detection monoclonal antibody is obtained. The monoclonal antibody for detecting the HPV16 type E7 protein is prepared by taking mouse splenocytes and myeloma cells to be fused to prepare hybridoma cells, then performing clone detection on the hybridoma cells to screen the hybridoma cells aiming at the specificity of the HPV16 type E7 protein, and finally obtaining the monoclonal antibody for detecting the HPV16 type E7 protein. According to the present invention, the HPV16 type E7 antigen detection kit is developed by using the immunochromatography method, and the kit has advantages of high sensitivity, strong specificity, simple operation and fast detection speed, and can be used for rapid screening diagnosis and illness state monitoring of HPV16.

The application belongs to the technical field of biotechnology, and provides a Streptococcus suis type 2 (SS2) multi-epitope inhalation subunit vaccine and application thereof.Four CTL epitopes, seven HTL epitopes and six B cell epitopes are screened from the conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, and the four CTL epitopes, the seven HTL epitopes and the six B cell epitopes are fused by AAY / GPGPG / EAAAK linkers and introduced into L7 / L12 ribosomal protein as an adjuvant to construct an inhalation subunit vaccine 1022-SpaA V3.The vaccine is intranasally primed and boosted at 60 μg, can improve respiratory mucosa sIgA and serum IgG levels, activate related immune cells, and form a mucosal and systemic double immune mechanism.The survival rate of mice after SS2 multi-strain challenge is up to 100%, and the bacterial load can be reduced.The vaccine is safe and non-toxic, inhalation can save cost, and is suitable for industrial scale production.

Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV.

The invention discloses a preparation method of an anti-human hepatitis B surface antigen monoclonal antibody. The preparation method comprises the following steps: step 1, extracting a human hepatitis B surface antigen HBsAg; 2, selecting an experimental animal, wherein the experimental animal is a mouse; 3, animal immunization is conducted on the mouse, purified antigen HBsAg is injected for immunization, and injection positions are subcutaneous and abdominal cavities; step 4, continuing to carry out second immunization and third immunization by using the same dose of antigen and the same method; step 5, using the same dosage of antigen and the same method to carry out booster immunization before cell fusion; 6, taking out the spleen of the mouse after three days of boosted immunization, preparing a cell suspension, preparing myeloma cells, and fusing the cell suspension and the myeloma cells into hybridoma cells; 7, screening hybridoma cells, and culturing and cloning the screened hybridoma cells; and 8, preparing ascites, and purifying the ascites to obtain the monoclonal antibody. Compared with the prior art, the invention has the advantage of providing the preparation method of the anti-human hepatitis B surface antigen monoclonal antibody with higher purity.

The application provides a vaccine against ichthyophthiriasis and a preparation method and application thereof, and belongs to the technical field of fish disease prevention and control. The application uses inactivated whole worms of in-vitro large-scale cultured Amphilina alata as a cross antigen, and fish complement C5a protein as an immunoadjuvant, and the two synergistically play a high-efficiency immune protection role. The application mixes and emulsifies the C5a adjuvant and the antigen at an effective dose of 1x10 4 6x10 4 per tail to prepare the vaccine. After intraperitoneal injection and secondary boosting, the vaccine produces significant cross protection against the infection of the ichthyophthirius, and the protection effect is significantly better than that of a traditional Freund's adjuvant vaccine. The application breaks the bottleneck that the ichthyophthirius cannot be cultured in vitro and thus a large number of worm bodies cannot be obtained for large-scale preparation of whole worm vaccines, and also solves the problem of poor safety of traditional adjuvants, has the advantages of low cost, good effect, easy large-scale production and the like, and is suitable for green immune prevention and control of ichthyophthiriasis of freshwater fish.

The application discloses a specific antibody targeting a lysine K1106 site of an ITSN1-S protein lactylation and a preparation method and application thereof, and the preparation method comprises the following steps: mixing and emulsifying an ITSN1-S-K1106 lactylation antigen with Freund's complete adjuvant and Freund's incomplete adjuvant respectively to obtain a first immunization liquid drop and a booster immunization liquid drop, performing animal immunization by using the first immunization liquid drop and the booster immunization liquid drop respectively, and separating the specific antibody targeting the lysine K1106 site of the ITSN1-S protein lactylation from blood of the immunized animal.The antibody provided by the application can specifically detect the lactylation modification condition of the human ITSN1-S protein from the cell and tissue levels in actual application, and is helpful to explore the action mechanism of post-translational modification of the ITSN1-S protein in tumor proliferation, migration and the like, and provides a potential action target for clinical diagnosis and treatment of tumor diseases.

The invention relates to the technical field of compositions for preventing and treating HPV, in particular to a composition for preventing and treating HPV and a preparation method and application thereof.The composition comprises anti-HPV specific egg yolk immunoglobulin (IgY) serving as an active ingredient, and the anti-HPV specific IgY is obtained through the method comprising the following steps that antigen preparation is conducted, specifically, an immunogen containing HPV main capsid protein L1 is prepared; animal immunization: carrying out stepped immunization, including basic immunization and periodic booster immunization, on the screened egg-laying poultry by adopting the immunogen so as to induce generation of a high-titer specific antibody; and antibody separation and purification: collecting highly immune eggs produced by immunized poultry, and separating and purifying the egg yolk to obtain the anti-HPV specific IgY. According to the present invention, the immunogen design of multivalent HPV L1 virus-like particles is adopted, and the efficient adjuvant is supplemented, such that the poultry is effectively induced to produce the high-titer neutralizing antibody with wide cross reactivity.

The present disclosure pertains to the field of vaccine technologies, with a focus on improved vaccine adjuvants and their formulations for enhancing immune responses. The described approach addresses limitations of traditional adjuvants by introducing novel formulations of the TLR7 agonist 1 V270, either as a standalone agent or in combination with co-adjuvants such as 2G272 and 2E151. These formulations include self-assembling nanoparticles, lipid-incorporated nanoparticles, and aqueous or liposomal combinations, designed to enhance antigen-specific immune responses while maintaining favorable safety and stability profiles. Notable advantages include balanced Thl / Th2 immune responses, dose¬ sparing effects, cross-reactive immunity, and compatibility with modern vaccine platforms such as mRNA vaccines. Applications encompass systemic and mucosal immunization against a wide range of pathogens, including influenza, SARS-CoV-2, and other infectious diseases. The described approach demonstrates enhanced immunogenicity, durability, and efficacy, particularly in aged populations and those requiring heterologous prime-boost regimens.